**Core Concept**
The underlying principle being tested is the pharmacological management of Alzheimer's disease, focusing on the cholinergic system. **Cholinesterase inhibitors** are a class of drugs used to treat Alzheimer's disease by increasing the concentration of **acetylcholine** in the brain. This is based on the cholinergic hypothesis of Alzheimer's disease, which suggests that a deficiency in cholinergic neurotransmission contributes to the cognitive decline observed in the disease.

**Why the Correct Answer is Right**
The correct answer involves the inhibition of **acetylcholinesterase**, the enzyme responsible for the breakdown of **acetylcholine**. By inhibiting this enzyme, drugs like tacrine, donepezil, rivastigmine, and galantamine increase the availability of **acetylcholine** in the synaptic cleft, thereby enhancing cholinergic neurotransmission. This mechanism is aimed at alleviating the cognitive and functional symptoms of Alzheimer's disease.

**Why Each Wrong Option is Incorrect**
**Option A:** This choice is incorrect because it does not accurately describe the primary mechanism of action of these drugs in the context of Alzheimer's disease.
**Option B:** Similarly, this option is incorrect as it does not align with the cholinergic enhancement strategy employed by these medications.
**Option C:** This choice is also incorrect because it misrepresents the therapeutic effect of these drugs on neurotransmitter systems in Alzheimer's disease.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that while **cholinesterase inhibitors** can provide symptomatic relief for Alzheimer's patients, they do not alter the disease's progression. Understanding the difference between symptomatic treatment and disease modification is crucial in managing patient expectations and designing treatment plans.

**Correct Answer:** Correct Answer: D. increase the concentration of acetylcholine in the brain.